(Q36905236)

17 August 2017

1 reference

title

The place of targeted therapy in the patient management of non-small cell lung cancer (English)

1 reference

17 August 2017

1 reference

Nicholas Thatcher

1

1 reference

17 August 2017

publication date

1 August 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

57 Suppl 2

1 reference

17 August 2017

page(s)

S18-23

1 reference

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970423-3

7 January 2021

10.1016/S0169-5002(07)70423-3

Identifiers

DOI

1 reference

release_swdgysllwfc2rfd5sodqamw3jm

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/swdgysllwfc2rfd5sodqamw3jm

24 November 2022

mapped directly with Wikidata item

1 reference